Moderna filed for an amended patent on coronavirus vaccine on March 28,2019... 9 months before the corona virus hit. In that amendment they claim a need for vaccine patent technology because of concern for re-emergence or a deliberate release of the SARS corona virus.
Moderna may not be able to release that vaccine at all because one of the key delivery systems of that vaccine was already patented by someone else. And Moderna along with backing from the US government is in violation of that patent.
The patent that was amended on March 28,2019 was actually a patent that a Moderna had been submitting since 2015 but had been rejected. They were adamant about the amended patent stating concerns about an “ACCIDENTAL OR DELIBERATE” release of the virus.
9 months later when Coronavirus emerges ... Moderna jumps up and says “Hey we are able to fight this” even though the US patent office had sent them a final rejection telling Moderna they could not have the patent.
However once the coronavirus hit .. political forces began to move behind the scenes and by May of 2020 .. Moderna was issued a patent on technology on the development of a vaccine for the coronavirus. But the story doesn’t end there.
Moderna has had numerous patent rejections due to dubious “double patenting” and a variety of other reasons. However in December of 2019 there was a contract between Moderna and the NIH to start developing vaccines using this technology that creates artificial spike proteins.
When virus comes around in Dec. 2019/January 2020 .. we then see Moderna being pushed to the frontlines with millions of dollars coming from the NIH and essentially from US taxpayers ... and not until MAY 2020 did they even have a patent approved on the technology.
Essentially the technology was never developed by Moderna but was developed by scientists at NIH who had filed their own royalty patents on the same technology. How is it that Moderna who had illegally secured patents on the MRNA technology failed to show this financially?
Moderna had $137 million of Federal Grant and Private funding for this technology .. NONE of which is acknowledged as it is REQUIRED to be in the patent application. They failed to follow the law. BUT MODERNA WAS PUSHED TO THE FOREFRONT BY THE NIAID AND ANTHONY FAUCI.
The NIAID and Fauci desperately wanted to have the moral front runner ... the NIAID for the vaccine and the economic victory because the NIAID has an enormous amount of the “core technology” patented and issued to themselves.
So the horse that was being bet on ... MODERNA... is not even qualified to run in the race. As Moderna money inflowed FIVE OF THE TOP EXECUTIVES AT MODERNA SOLD OVER $500 MILLION OF THEIR OWN STOCK. Now “patent infringement” happens with Moderna/NIH.
The lipid nanopartivle ... the liquid envelope in which the MRNA vaccine is delivered that was granted to Moderna came about over a bizarre custody battle on the “core” technology between 2 companies in the Pacific Northwest British Colombia/Vancouver area into Washington State.
Moderna is NOT liscensed to use this “core” technology. However it is likely the individuals involved had inside information that would put them in line for HUGE amounts of Federal funding because otherwise you would not have this very odd amendment to a rejected patent.
Moderna KNEW due to insider information that they were being positioned to deal with a beta coronavirus vaccine 9 MONTHS BEFORE the public was told there was an issue with coronavirus. This raises a serious set of questions that don’t look good with execs selling their stock.
All information provided by Dr. David Martin and Ben Swann here.👇

https://www.facebook.com/124075334324092/posts/3482401651824760/?vh=e&extid=ORsVdDiih9Z8kiy0
Now consider that THE CARES ACT was introduced on March 19,2019 ... nine days BEFORE Moderna submitted their amended patent application. Raise your hand if you smell a rat.
You can follow @betsy1954.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.